GlaxoSmithKline Settles Majority of Zantac Lawsuits for $2.2 Billion Amid Cancer Risk Allegations

GlaxoSmithKline has reached a settlement totaling $2.2 billion to resolve the majority of lawsuits related to Zantac, an antacid that has faced scrutiny over potential health risks. This agreement, announced on Wednesday, effectively concludes 93% of the cases brought against the company in state courts. The legal battle has centered around claims that the drug was linked to cancer, sparking hundreds of lawsuits from individuals who alleged harm. For further details on the settlement, interested readers can access the information via the original report.